{"bill": {"#text": "\n  ", "form": {"current-chamber": {"#tail": "\n    ", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n", "congress": {"#tail": "\n    ", "#text": "113th CONGRESS"}, "#tail": "\n  ", "legis-num": {"#tail": "\n    ", "#text": "S. 2862"}, "official-title": {"#tail": "\n  ", "#text": "To amend the Controlled Substances Act with respect to drug scheduling recommendations by the\n\t\t\t Secretary of Health and Human Services, and with respect to registration\n\t\t\t of manufacturers and distributors seeking to conduct clinical testing, and\n\t\t\t for other purposes. "}, "session": {"#tail": "\n    ", "#text": "2d Session"}, "distribution-code": {"#tail": "\n    ", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n      ", "@date": "20140918", "#text": "September 18, 2014"}, "#tail": "\n    ", "action-desc": {"#tail": "\n    ", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "SSHR00", "#text": "Committee on Health, Education, Labor, and Pensions"}, "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Hatch", "@name-id": "S118"}, "cosponsor": {"#tail": ") introduced the following bill; which was read twice and referred to the ", "#text": "Mr. Whitehouse", "@name-id": "S316"}}, "#text": "\n      "}, "legis-type": {"#tail": "\n    ", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014", "@value": "Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H50C178AFA00F4508B6D6A6560D7B53ED"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by inserting after\n\t\t\t subsection (h) the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 201 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:201"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 811", "@value": "usc/21/811"}, "@parsable-cite": "usc/21/811", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Scheduling of substances included in new FDA-approved drugs"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "subsection": {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " to add a drug or substance that has\n\t\t\t never been marketed in the United States to a schedule under this title,\n\t\t\t the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall, without regard to the findings required by\n\t\t\t subsection (a) of this section or ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ", issue an interim final\n\t\t\t rule, under the exception for good cause described in ", "@entity-type": "act", "#text": "section 202(b)", "@value": "Controlled Substances Act/s:202/ss:b"}, {"#tail": ", placing the drug or\n\t\t\t substance into the schedule recommended by the ", "@entity-type": "uscode", "#text": "subparagraph (B) of\n\t\t\t ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc/5/553", "#text": "section 553(b)", "@legal-doc": "usc"}, "@value": "usc/5/553/b//B"}, {"#tail": ". The interim\n\t\t\t final rule shall be made immediately effective under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "uscode", "#text": "section 553(d)(3) of\n\t\t\t title 5, United States Code", "@value": "usc/5/553/d/3"}], "#text": "Within 45 days of receiving a recommendation from the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(i)"}, "@id": "H956A198CA01D4E9699386C70F5CD2DFE", "#text": "\n          "}, "#text": "\n        ", "@id": "HF92623B6E0604C849F1CB660CB9CF7B9"}, "#text": "\n      ", "@id": "H99F61C2A5E3C4A798F9F2149DD18DFE0"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by inserting after\n\t\t\t subsection (g) the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 302 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:302"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 822", "@value": "usc/21/822"}, "@parsable-cite": "usc/21/822", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Enhancing new drug development"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "subsection": {"#tail": "\n        ", "#text": "\n          ", "enum": {"#tail": "\n          ", "#text": "(h)"}, "@id": "HF2A73ADF44F54B218F20AFB7008F5C92", "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505(i) of the Federal\n\t\t\t Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, "#text": "A person who submits an application for registration to manufacture or distribute a controlled\n\t\t\t substance in accordance with this section may indicate on the registration\n\t\t\t application that the substance will be used only in connection with\n\t\t\t clinical trials of a drug in accordance with "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@display-inline": "yes-display-inline", "#text": "\n            ", "@id": "HDD63E7052F8E473FA3B96EE446648EDB", "@commented": "no"}, {"@indent": "up1", "#tail": "\n        ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "section\n\t\t\t 505(i) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, {"#tail": "\n\t\t\t shall\u2014", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "When an application for registration to manufacture or distribute a controlled substance includes\n\t\t\t an indication that the controlled substance will be used only in\n\t\t\t connection with clinical trials of a drug in accordance with "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "H651AEA7933CD43319C7BA55231DE9DD9", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "make a final decision on the application for registration within 180 days; or"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H3942D2C99E324569A4794CC20039393A", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "#text": "provide notice to the applicant in writing of\u2014"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "the outstanding issues that must be resolved in order to reach a final decision on the application;\n\t\t\t and"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H41FD75B83D884EF2A12A07311FF5C866", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "the estimated date on which a final decision on the application will be made."}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H1050D99947004C93B7AE35C5AF3884B1", "#text": "\n                "}], "#text": "\n              ", "@id": "HBC6ACE82E98E4FE39214CD01729720E1"}]}]}, "#text": "\n        ", "@id": "HC162F4D7FAF94B0AA24C8186367E9B1A"}, "#text": "\n      ", "@id": "H3DB6FFA0B1A74E0EB1E5F0DD55D30F01"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Registration process under Controlled Substances Act"}, "subsection": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the\n\t\t\t following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 303 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 823", "@value": "usc/21/823"}, "@parsable-cite": "usc/21/823", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Factors as may be relevant to and consistent with the public health and safety"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "subsection": {"#tail": "\n            ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 101", "@value": "Controlled Substances Act/s:101"}, "quote": {"#tail": " means factors that are relevant to and consistent with the findings contained in ", "#text": "factors as may be relevant to and consistent with the public health and safety"}, "#tail": "\n            ", "#text": "In this section, the phrase ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(i)"}, "@id": "HC569CBA06D4C441EBBFAD425B60CF527", "#text": "\n              "}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "H363843CE43714E49AB156F60AAB21DB1"}, "#text": "\n          ", "@id": "H22FA1DC728154998BCE7EE52F234919D"}, {"#tail": "\n      ", "@id": "H900618BBCC944BB8BCC639DC372E5130", "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Imminent danger to the public health or safety"}, "text": {"#tail": "\n          ", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 304(d) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:304/ss:d"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 824(d)", "@value": "usc/21/824/d"}, "@parsable-cite": "usc/21/824", "#text": "\n              ", "@legal-doc": "usc"}}}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "quote": [{"#tail": " and inserting ", "#text": "(d) The Attorney General\n              "}, {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, "#text": "(d)(1) The "}], "#text": "by striking "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "HEFBB9A0247584D26BEC2EB0DCCD49C04", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n            ", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "."}, "#tail": "\n          ", "paragraph": {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n                ", "term": {"#tail": " means that, in the absence of an immediate suspension order, controlled substances will continue\n\t\t\t to be distributed or dispensed by a registrant who knows or should know\n\t\t\t through fulfilling the obligations of the registrant under this Act, or\n\t\t\t has reason to\n\t\t\t believe that\u2014", "#text": "imminent danger to the public health or safety"}, "#text": "In this subsection, the phrase ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "#text": "\n                ", "@id": "H7C924D2D4300454084F72F687BDFFECE", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "the dispensing is outside the usual course of professional practice;"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "idB02483A43EBB48CEA74AE9BD4EB5F683", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "the distribution or dispensing poses a present or foreseeable risk of adverse health consequences\n\t\t\t or death due to the abuse or misuse of the controlled substances; or"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "id7F47C60A80FD4934A802C91D108492B8", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "the controlled substances will continue to be diverted outside of legitimate distribution channels."}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "id9F0A2C0302A4474BB99F6A6E5D7F53FE", "#text": "\n                  "}]}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "HDEF025DDA7BA4A52B7C7F6B6761B987D"}, "#text": "\n            ", "@id": "H4138CA7EE7C94012821D34183B7874E5"}]}], "#text": "\n        ", "@id": "H5306A535106842CEA7168B562BABAC6E"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Subsection (c) of section 304 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:304/ss:c"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 824", "@value": "usc/21/824"}, "@parsable-cite": "usc/21/824", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Opportunity To submit corrective action plan prior to revocation or suspension"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "by striking the last two sentences;"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HF86ED9E88D30482C87DB31431C217892", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " and inserting ", "#text": "(c) Before"}, {"#tail": "; and", "#text": "(c)(1) Before"}], "#text": "by striking "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H01F77CA56680471B96B9E7936C123503", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n          ", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "paragraph": [{"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "An order to show cause under paragraph (1) shall\u2014"}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "#text": "\n              ", "@id": "H818C725CA32941F5AE4C7B4FF743064F", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "contain a statement of the basis for the denial, revocation, or suspension, including specific\n\t\t\t citations to any laws or regulations alleged to be violated by the\n\t\t\t applicant or registrant;"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H7DC04F26446D43BBA5C365797A994BA4", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " at a time and place stated\n\t\t\t in the order, but not less than 30 days after the date of receipt of\n\t\t\t the order; and", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, "#text": "direct the applicant or registrant to appear before the "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H58F9BAD54DF947388CBCFC0074A7E79F", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "notify the applicant or registrant of the opportunity to submit a corrective action plan on or\n\t\t\t before the date of appearance."}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "H81EBEE957CBB4B5193ABFB19D42B4A03", "#text": "\n                "}]}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall determine whether denial,\n\t\t\t revocation or suspension proceedings should be discontinued, or deferred\n\t\t\t for the purposes of modification, amendment, or clarification to such\n\t\t\t plan.", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, "#text": "Upon review of any corrective action plan submitted by an applicant or registrant pursuant to\n\t\t\t paragraph (2), the "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "#text": "\n              ", "@id": "HDDAEB68EE86C46EF846AD61851444FFE"}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ". Such\n\t\t\t proceedings shall be\n\t\t\t independent of, and not in lieu of, criminal prosecutions or other\n\t\t\t proceedings under this title or any other law of the United States.", "@entity-type": "uscode", "#text": "subchapter II of ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc-chapter/5/5", "#text": "chapter 5", "@legal-doc": "usc-chapter"}, "@value": "usc-chapter/5/5/II"}, "#text": "Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance\n\t\t\t with "}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "#text": "\n              ", "@id": "HC341FA78C8EC4E3CBB1E42489F7E23F6"}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "The requirements of this subsection shall not apply to the issuance of an immediate suspension\n\t\t\t order under subsection (d)."}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "#text": "\n              ", "@id": "H36C826AE1CBE4AFE9602499F09552B68"}], "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "H14A81C371A124B00B74C1BB759D2A90F"}, "#text": "\n          ", "@id": "H96F65A1C309343CEB8A271E50783F677"}], "#text": "\n        ", "@id": "H919D5C29D791499D832B0BC019DE76A9"}], "#text": "\n      ", "@id": "HCE607419F1D34D6EB8A11EC312ECD226"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n      ", "#text": "Report to Congress on effects of law enforcement activities on patient access to medications"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human\n\t\t\t Services", "@entity-id": "7500"}, {"#tail": " and the\n\t\t\t ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, {"#tail": ", and in\n\t\t\t consultation with the ", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}, {"#tail": "\n\t\t\t and the ", "@entity-type": "federal-body", "#text": "Administrator of the Drug Enforcement Administration", "@entity-id": "1524"}, {"#tail": ", shall submit a report to\n\t\t\t the ", "@entity-type": "federal-body", "#text": "Director of National Drug Control Policy", "@entity-id": "1127"}, {"#tail": ", the\n\t\t\t ", "@entity-type": "committee", "#text": "Committees on the Judiciary of the House of Representatives", "@entity-id": "HJU00"}, {"#tail": ", the\n\t\t\t ", "@entity-type": "committee", "#text": "Committee on Energy and Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": ", and the ", "@entity-type": "committee", "#text": "Committee on the Judiciary of the Senate", "@entity-id": "SSJU00"}, {"#tail": " identifying\u2014", "@entity-type": "committee", "#text": "Committee on Health,\n\t\t\t Education, Labor and Pensions of the Senate", "@entity-id": "SSHR00"}], "#text": "Not later than 1 year after the date of enactment of this Act, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "obstacles to legitimate patient access to controlled substances;"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HD2C44B04DD6A410D90EAD7172EA7BEFB", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "issues with diversion of controlled substances; and"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H2BC13C38B23E48C98ADC53AE2A19F530", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "how collaboration between Federal, State, local, and tribal law enforcement agencies and the\n\t\t\t pharmaceutical industry can benefit patients and prevent diversion and\n\t\t\t abuse of controlled substances."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "H21717A3FD57A44448BD166B441E02C96", "#text": "\n          "}], "#text": "\n        ", "@id": "HFD8E94DA3E174658B6776898F6C155B7"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "#text": "The report under subsection (a) shall incorporate feedback and recommendations from the following:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Consultation"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Patient groups."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H092E27C086584A9FB8D1B652B975F6FD", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Pharmacies."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H5CD65F75C12849BDA6D28D3B4B888192", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Drug manufacturers."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "H9469E001598C4B808B8554CF74A3EAE5", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Common or contract carriers and warehousemen."}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "H4C1B8E43FFE643FE9E5FAFB80C1C3D6B", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Hospitals, physicians, and other health care providers."}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "@id": "HECACCE814CF34A90AD1D19D19CAA8931", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "State attorneys general."}, "enum": {"#tail": "\n          ", "#text": "(6)"}, "@id": "HA5BEFFAC62054C27B0C0FFC7FA48F57C", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Federal, State, local, and tribal law enforcement agencies.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(7)"}, "@id": "H44FB8066A4584465AEAB20596F6A349C", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Health insurance providers and entities that provide pharmacy benefit management services on behalf\n\t\t\t of a health insurance provider."}, "enum": {"#tail": "\n          ", "#text": "(8)"}, "@id": "HBF1D70DCC8A34E7098D1B9295EF8D2CF", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "Wholesale drug distributors."}, "enum": {"#tail": "\n          ", "#text": "(9)"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "HF98C2C07D6FB4FB9A1007FC08F5C1729", "@commented": "no"}], "#text": "\n        ", "@id": "H7DED1A4A89A7442EA504E8EC24DF85E9"}], "#text": "\n      ", "@id": "HA72B90AD1F004BD59C5A71765787DF1B"}], "#text": "\n    ", "@id": "H3D7856030F154CAB9CA7B3EE1120FC3D"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-09-18"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S2862 IS: Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}